Position in NGNE
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$1,446
+$519 QoQ
Shares Held
46
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#100
of 112 holders
Holding Since
Sep 2023
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NGNE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Truvestments Capital LLC holds $2,122,733 across 78 Biotechnology names. NGNE ranks #60 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
|
7,833 | $426,193 | |
| 2 | CRVS |
Corvus Pharmaceuticals, Inc.
|
10,195 | $152,313 | |
| 3 | PTGX |
Protagonist Therapeutics, Inc
|
1,156 | $141,702 | |
| 4 | ROIV |
Roivant Sciences Ltd.
|
3,788 | $134,057 | |
| 5 | CTMX |
CytomX Therapeutics, Inc.
|
27,988 | $104,955 | |
| 6 | TGTX |
Tg Therapeutics, Inc.
|
1,764 | $96,914 | |
| 7 | RIGL |
Rigel Pharmaceuticals Inc
|
2,387 | $93,379 | |
| 8 | BBIO |
BridgeBio Pharma, Inc.
|
1,229 | $91,535 |
All Filings in NGNE
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,446 | 46 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $927 | 46 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $947 | 46 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $797 | 46 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $687 | 46 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $538 | 46 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $1,051 | 46 | Shares | Sole | 2025-02-10 | |
| 2024-09-30 | $1,930 | 46 | Shares | Sole | 2024-11-13 | |
| 2024-03-31 | $2,341 | 46 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $891 | 46 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 NLTX | — | 185 | Shares | Sole | 2023-11-13 | |
| No filing history on record for this holder in this stock. | ||||||